Efficacy of volumetric intensity modulated arc therapy (VMAT) combined with chemotherapy in anal squamous cell carcinoma
10.3760/cma.j.issn.0254-5098.2019.08.009
- VernacularTitle:容积旋转调强放疗联合化疗治疗肛管鳞癌的疗效分析
- Author:
Hongzhi WANG
1
;
Yangzi ZHANG
;
Jianhao GENG
;
Xianggao ZHU
;
Yongheng LI
;
Yong CAI
;
Weihu WANG
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所放射治疗科恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- Keywords:
Anal squamous cell carcinoma;
Volumetric intensity modulated arc therapy;
Concurrent chemotherapy;
Efficacy;
Toxicity
- From:
Chinese Journal of Radiological Medicine and Protection
2019;39(8):609-613
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of concurrent chemoradiotherapy for anal squamous cell carcinoma (ASCC) in the era of intensity-modulated radiotherapy.Methods A total of 19 patients with ASCC who underwent definitive radiotherapy in our hospital since 2011 were collected.The survival curves were depicted with K-M method.Risk factors of disease progression were analyzed using case-control study.Results The median follow-up time was 31 months.The 3 year-LFS and 3 year-OS were 88.1％ and 91.7％,respectively.Grade 3 acute toxicities during the chemoradiotherapy were mainly white blood cell reduction (15.8％),platelet reduction (10.5％),diarrhea (15.8％),and skin reaction (31.6％).Compared with historical data,volumetric intensity modulated arc therapy was superior to conventional radiotherapy in the treatment outcome and normal tissue protection in ASCC.Univariate analysis showed that concurrent chemotherapy with capecitabine was a favorable factor in disease progression (P＜ 0.05).Conclusions Volumetric intensity modulated arc therapy for ASCC may have advantages in terms of efficacy and normal tissue protection.Concurrent chemotherapy with a double-drug regimen containing capecitabine may be a beneficial factor in disease progression.
